Category Archives: Stem Cell Research

This acquisition expands the operational footprint of Generate Life Sciences across three countries, alongside its distribution network for frozen donor gametes in more than 40 countries. In particular, it further increases access to newborn stem cell preservation and genetic screening services across North America. "Generate Life Sciences is the natural partner for Cell Care given our established industry and scientific leadership in our respective markets," says Brent Dennison, Chief Executive Officer of Cell Care. Continue reading →

Deafness is the most common sensory impairment in newborn children about 1 child in 1000 is born with hearing loss, or develops it in early childhood.Half of these cases have a genetic cause; very often, this type of deafness is related to a mutation of a gene called 'gap junction beta 2 (GJB2)', which encodes a protein called 'connexin 26 (CX26)'. This protein occurs in cells in the cochlea, the part of the inner ear enabling hearing. One way of treating GJB2-related deafness would be to reproduce properly functioning cochlear cells and introduce them into the inner ear Continue reading →

Caption By: Peter Marks, M.D., Director, Center for Biologics Evaluation and Research The U.S. Food and Drug Administration continues to facilitate the development and availability of innovative medical products, such as regenerative medicine therapies, that have the potential to treat or even cure diseases or conditions for which few effective treatment options exist. For example, the agency has recently licensed (approved) its first product that received Regenerative Medicine Advanced Therapy (RMAT) designation, underscoring our ongoing commitment to work with sponsors and manufacturers to bring these products to market Continue reading →

DUBLIN, June 4, 2021 /PRNewswire/ -- The "Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Cell Type, End User, and Geography" report has been added to ResearchAndMarkets.com's offering. The global cell therapy bioprocessing market is expected to reach US$ 30,052.61 million in 2028 from US$ 11,192.50 million in 2020. The market is estimated to grow with a CAGR of 13.14% from 2020 to 2028. Continue reading →

June 4, 2021 John Theurer Cancer Center investigators report new findings at American Society of Clinical Oncology 2021 Annual Meeting Researchers from Hackensack University Medical Centers John Theurer Cancer Center, a part of Georgetown Lombardi Comprehensive Cancer Center, are presenting data from 25 studies at the Annual Meeting of the American Society of Clinical Oncology, the largest gathering of cancer professionals in the country. This years meeting is being held virtually June 4-8, 2021. Abstracts of the studies can be viewed at abstracts.asco.org. Continue reading →

SAN DIEGOandSTOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento")today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, KarolinskaInstitutet(KI) inStockholm, Sweden, aimed at producing novelcell-based therapeutics using natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs). Sorrento and KI are collaborative partners in the Competence Center for the development of next-generation NK cell-based cancer immunotherapies (NextGenNK) coordinated by KI. Continue reading →

The stem cell banking is the practice of preserving blood cell from a new born baby for future use. The preserved blood is used in medical therapies for a variety of diseases, which include conditions such as sarcoma, leukemia, immune conditions, lymphoma, and metabolic disorders. Continue reading →

According to research published in Nature Communications, investigators developed a new single-cell multi-omic approach to identify leukemic stem cells and characterized cancer stem cells in the context of acute myeloid leukemia (AML), which the investigators think may be able to translate to other tumor types.1 MutaSeq, the new method created by investigators from the Centre for Genomic Regulation (CRG) and the European Molecular Biology Laboratory (EMBL), works to distinguish between pre-leukemic stem cells, leukemic stem cells, and healthy hematopoietic stem cells.2 There are a huge number of small molecule drugs out there with demonstrated clinical safety, but deciding which cancers and more specifically which patients these drugs are well suited for is a daunting task, Lars Steinmetz, professor at Stanford University and author of the paper, said in a press release. Our method can identify drug targets that might not have been tested in the right context. These tests will need to be carried out in controlled clinical studies, but knowing what to try is an important first step. Continue reading →

The UCLA study has found that a one-time injection of an experimental stem cell therapy can promote recovery by repairing brain damage and improving memory function in mice with conditions that replicate human strokes and dementia. Dementia is characterised by an array of symptoms including problems with memory, attention, communication, and physical coordination with the two most common causes of dementia bring Alzheimers disease and white matter strokes. The study has been published inScience Translational Medicine. Continue reading →

26 April 2021 Adult human skin cells have been reprogrammed to form three-dimensional structures similar to early human embryos by a team led by Professor Jose Polo at Monash University, Australia (see BioNews 1088). Called 'iBlastoids', they could potentially enable us to learn how early human embryos develop and implant in the uterus. The studies could also lead to medical treatments for conditions such as infertility, miscarriage, developmental disorders and genetic diseases Continue reading →